Physician profile
Sarah Routh
NPI 1619497682
$7,931.86
in general payments reported to CMS, 2019-2025
52 companies · $1,539 in 2025
The $1,539 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,403 · 2022: $1,439 · 2023: $1,714 · 2024: $1,837 · 2025: $1,539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,090.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,090.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,003.82 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,002.84 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $859.31 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $688.19 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $367.96 | 2021-2025 | Jardiance |
| Pfizer INC. | $355.44 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $300.04 | 2021-2024 | Verquvo, Belsomra, Gardasil 9 |
| Bayer Healthcare Pharmaceuticals INC. | $299.45 | 2021-2025 | |
| Amgen INC. | $294.11 | 2021-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $279.92 | 2021-2024 | Trelegy Ellipta, Shingrix |
| Axsome Therapeutics, INC. | $262.66 | 2024 | Auvelity |
| Astellas Pharma US INC | $186.09 | 2021-2025 | Veozah, Myrbetriq |
| Esperion Therapeutics, INC. | $149.36 | 2021-2025 | Nexletol |
| Exact Sciences Corporation | $134.43 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sumitomo Pharma America, INC. | $120.91 | 2023-2025 | Gemtesa |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Routh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.